Drug Profile
Research programme: liver X receptor modulators - Yuhan Corporation
Alternative Names: YH-LXR; YH_LXRLatest Information Update: 16 Dec 2014
Price :
$50
*
At a glance
- Originator Yuhan
- Class Small molecules
- Mechanism of Action Liver X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 16 Dec 2014 No development reported - Preclinical for Atherosclerosis in South Korea (PO)
- 31 Dec 2011 Preclinical trials in Atherosclerosis in South Korea (PO)